Close mobile menu×
Close mobile menu

Ran Reshef, MD

Expertise in: 
Blood and Marrow Stem Cell Transplantation, Hematology/Oncology
Accepting New Patients
Virtual Visits/Telehealth
Profile Headshot

Schedule an Appointment

Virtual Visits/Telehealth

Virtual Visits allow you to connect with your provider from the comfort, convenience, and safety of your own home.

Schedule Virtual Visit

Phone Appointments

New and Existing Patients:

Connect Patient Portal

For existing patients, login to make an appointment, view documentation or contact your care provider.

Connect Sign In

Credentials & Experience

Clinical Expertise

  • Amyloidosis
  • Bone Marrow Transplant
  • Cancer Immunotherapy
  • Cellular Therapy
  • Leukemia
  • Lymphoma
  • Multiple Myeloma


Education & Training

  • MD, 2003 Medicine, Sackler School of Medicine, Tel Aviv University (Israel)
  • MSc, 2011 Translational Research, Perelman School of Medicine University of Pennsylvania
  • Internship: 1998 Tel Aviv Sourasky Medical Center, Israel
  • Residency: 2007 Tel Aviv Sourasky Medical Center, Israel
  • Fellowship: 2009 Perelman School of Medicine University of Pennsylvania

Honors & Awards

  • Sternberg Research Award, Abramson Cancer Center, University of Pennsylvania (2008)
  • Bradley Fellow Research Award, Department of Medicine, University of Pennsylvania (2011)
  • Austrian Junior Faculty Award, Department of Medicine, University of Pennsylvania (2012)
  • Amy Strelzer Manasevit Award for the Study of Post-Transplant Complications, National Marrow Donor Program (2013)

About Ran Reshef

Dr. Reshef trained in Hematology, Oncology and Bone Marrow Transplantation and received a Master of Science degree in Translational Research from the University of Pennsylvania. He joined Columbia University in 2015 as Director of Translational Research for the Blood and Marrow Transplantation program. He is the Clinical Lead for the CAR-T Cell Program at Columbia, a principal investigator at the Columbia Center for Translational Immunology and a member of the Herbert Irving Comprehensive Cancer Center.

Academic Titles

  • Associate Professor of Medicine at CUMC

Administrative Positions

  • Director, Translational Research, Blood and Marrow Transplantation
  • Clinical Lead, CAR-T Cell Program

Committee/Societies/Council Memberships

American Society of Clinical Oncology

American Society of Hematology

American Society of Blood and Marrow Transplantation

Center for International Blood and Marrow Transplant Research

Bone Marrow Transplant Clinical Trials Network Steering Committee

Mount Sinai Acute GvHD International Consortium

American Journal of Hematology (Editorial Board)

National Institues of Health (Study Section)

Department of Defense (Study Section)

Hospital Affiliations

  • NewYork-Presbyterian / Columbia University Irving Medical Center


  • Hebrew


  • Male

Insurance Accepted


  • Aetna Signature Administrators
  • EPO
  • HMO
  • Medicare Managed Care
  • NYP Employee Plan
  • NY Signature
  • POS
  • PPO
  • Student Health

Affinity Health Plan

  • Essential Plan
  • Medicaid Managed Care


  • Medicare Managed Care
  • Special Needs

Amida Care

  • Special Needs

Capital District Physician Health Plan

  • Capital District Physician Health Plan


  • EPO
  • Great West (National)
  • HMO
  • POS
  • PPO


  • Medicare Managed Care
  • PPO

Empire Blue Cross/Blue Shield

  • EPO
  • Medicare Managed Care
  • PPO

Fidelis Care

  • Child/Family Health Plus
  • Medicaid Managed Care
  • Medicare Managed Care

Health First

  • Child/Family Health Plus
  • Leaf (Exchange)
  • Medicaid Managed Care
  • Medicare Managed Care

Health Insurance Plan of NY (HIP)

  • ConnectiCare
  • EPO
  • Essential Plan
  • HMO
  • Medicaid Managed Care
  • Medicare Managed Care
  • POS
  • PPO
  • Select Care (Exchange)
  • Vytra

Health Plus - Amerigroup

  • Child/Family Health Plus
  • Essential Plan
  • Medicaid Managed Care

Local 1199

  • Local 1199

MagnaCare (National)

  • MagnaCare


  • Traditional Medicare


  • Multiplan

MVP Health Care

  • Child/Family Health Plus
  • Essential Plan
  • HMO
  • Medicaid Managed Care

Oxford Health Plans

  • Freedom
  • Liberty

United Health Care

  • Columbia Employee POS
  • Compass (Exchange)
  • HMO
  • Medicaid (Community Plan)
  • Medicare Managed Care
  • POS
  • PPO


  • Medicare Managed Care
  • Select Health
  • Special Needs


  • Medicaid Managed Care
  • Medicare Managed Care

*Please contact the provider’s office directly to verify that your particular insurance is accepted.

Contact & Locations

161 Fort Washington Avenue
New York, New York 10032


The Reshef lab combines efforts in both basic research and clinical investigation to advance the understanding of immune responses following hematopoietic stem-cell transplantation and other forms of cell therapy.

The lab is focused on two primary areas:

1. Investigating lymphocyte migration mechanisms and how they affect the clinical and immunologic outcomes of stem-cell transplantation. The lab pioneered the use of chemokine receptor blockade after allogeneic stem-cell transplantation to reduce immune-mediated complications.

2. Developing methodologies for the study of human samples from transplant recipients at the single-cell level in order to unravel novel immunologic mechanisms that would lead to new therapeutic approaches. The lab works with blood, stool and tissue samples and uses a diverse toolset that includes genomic and immunophenotypic methods to identify new therapeutic modalities. Our ultimate goal is to identify new targets that improve transplant outcomes using evidence in both mice and humans and to test these targets clinically.

Dr. Reshef’s research is funded by the National Cancer Institute, Conquer Cancer Foundation, National Marrow Donor Program and Department of Defense. He previously received awards from the Leukemia & Lymphoma Society and the American Society of Hematology.

Selected Publications

  1. Reshef R, Luger SM, Hexner EO, Loren AW, Frey NV, Nasta, SD, Goldstein SC, Stadtmauer EA, Smith J, Bailey S, Mick R, Heitjan DF, Emerson SG, Hoxie J, Vonderheide RH, Porter DL (2012). "Effect of Blocking Lymphocyte Chemotaxis on Visceral Graft-vs-Host Disease." N Engl J Med 367:135-145
  2. Reshef R, Huffman AP, Gao A, Luskin MR, Hexner EO, Loren AW, Frey NV, Stadtmauer EA, Luger SM, Mangan JK, Nasta SD, Gill SI, Sell M, Kambayashi T, Richman LP, Vonderheide RH, Mick R, Porter DL (2015). "High Graft CD8 Cell Dose Predicts Improved Survival and Enables Better Donor Selection In Allogeneic Stem-Cell Transplantation With Reduced-Intensity Conditioning" J Clin Oncol 33:2392-2398.
  3. Ryan H. Moy, Austin P. Huffman, Lee P. Richman, Lisa Crisalli, Ximi K. Wang, James A. Hoxie, Rosemarie Mick, Stephen G. Emerson, Yi Zhang, Robert H. Vonderheide, David L. Porter and Ran Reshef (2017) "Clinical and immunologic impact of CCR5 blockade in graft-versus-host disease prophylaxis" Blood 129:906-916
  4. Mishkin AD, Mapara MY, Reshef R (2018). "Iatrogenic Infertility After Curative Stem Cell Transplantation in Sickle Cell Disease Patients". Ann Intern Med 2018 Jun 19;168(12):881-88